Background
On 8-10 September 2014, WHO convened the first meeting of the new Product Development for Vaccines Advisory Committee. This new Committee fills a previous gap in WHO’s advisory structure for vaccines by providing a horizon-scanning role across upstream (preclinical to Phase 2) pre-licensure vaccine research and disease for diseases of potential priority to WHO.
In addition to review of and strategic discussion across 10 disease areas, key cross-cutting issues in pre-licensure vaccine R&D were considered, such as Public Disclosure of Clinical Trial Results, and WHO’s Position in this regard. Secondly the area of human challenge trials for evaluation of vaccines was discussed.
The agenda, list of participants and presentations can be found below: